ABSTRACT
Background SARS-CoV-2-specific antibodies may protect from reinfection and disease, providing the rationale for administration of plasma containing SARS-CoV-2 neutralizing antibodies (nAb) as a treatment for COVID-19. The clinical factors and laboratory assays to streamline plasma donor selection, and the durability of nAb responses, are incompletely understood.
Methods Adults with virologically-documented SARS-CoV-2 infection in a convalescent plasma donor screening program were tested for serum IgG to SARS-CoV-2 spike protein S1 domain, nucleoprotein (NP), and for nAb.
Results Amongst 250 consecutive persons studied a median of 67 days since symptom onset, 243/250 (97%) were seropositive on one or more assays. Sixty percent of donors had nAb titers ≥1:80. Correlates of higher nAb titer included older age (adjusted OR [AOR] 1.03/year of age, 95% CI 1.00-1.06), male sex (AOR 2.08, 95% CI 1.13-3.82), fever during acute illness (AOR 2.73, 95% CI 1.25-5.97), and disease severity represented by hospitalization (AOR 6.59, 95% CI 1.32-32.96). Receiver operating characteristic (ROC) analyses of anti-S1 and anti-NP antibody results yielded cutoffs that corresponded well with nAb titers, with the anti-S1 assay being slightly more predictive. NAb titers declined in 37 of 41 paired specimens collected a median of 98 days (range, 77-120) apart (P<0.001). Seven individuals (2.8%) were persistently seronegative and lacked T cell responses.
Conclusions Nab titers correlated with COVID-19 severity, age, and sex. Standard commercially available SARS-CoV-2 IgG results can serve as useful surrogates for nAb testing. Functional nAb levels were found to decline and a small proportion of COVID-19 survivors lack adaptive immune responses.
Competing Interest Statement
A.L.G. reports consulting fees from Abbott Molecular, outside of the submitted work.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT04344977
https://clinicaltrials.gov/ct2/show/NCT04338360
Funding Statement
This work was supported by the Fred Hutchinson Joel Meyers Endowment (J.B.), Fast-Grants (J.B.), a new investigator award from the American Society for Transplantation and Cell Therapy (J.B.), NIH contract 75N93019C0063 (D.M.K), NIH T32-AI118690 (D.Z.), NIH T32-AI007044 (S.M.), NIH K08-AI119142 (S.L.F.), and NIH K23-AI140918 (A.E.S.). The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services (DHHS) or of the institutions and companies affiliated with the authors. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201800013C. R.G., J.L., and M.R.H. performed this work as employees of Laulima Government Solutions, LLC. A subcontractor to Laulima Government Solutions, LLC who performed this work is E.P., an employee of Tunnell Government Services, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board approval was obtained from the University of Washington and all participants underwent informed consent form.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Relevant data are available from the corresponding author on request.
ABBREVIATIONS
- DMSO
- dimethylsulfoxide
- PCR
- polymerase chain reaction
- EDTA
- ethylenediamine tetra-acetic acid
- SARS-CoV-2
- severe adult respiratory syndrome coronavirus 2
- COVID-19
- coronavirus disease 2019
- OR
- odds ratio
- CI
- confidence interval
- IgG
- immunoglobulin G
- BSL-3
- biosafety level 3
- nAb
- neutralizing antibody
- ROC
- receiver operating curve
- S1
- spike protein domain 1
- NP
- nucleoprotein
- PBMC
- peripheral blood mononuclear cells
- ACE2
- angiotensin converting enzyme 2
- CE
- Conformité Européenne
- ELISA
- enzyme linked immune sorbent assay
- ODR
- optical density ratio
- FRNA
- fluorescence reduction neutralization assay
